Chief Business Officer, Resilience
As Chief Business Officer, Alex is focused on strategic transactions that help embed Resilience into the future of next-generation preventative, regenerative and curative therapies and vaccines. Alex and his team support and lead risk-sharing arrangements, equity purchases, newco generation and strategic relationships with academic institutions and life sciences incubators spanning R&D (Res-X) and Digital divisions as well as innovators across Resilience’s modality franchises (cell therapy, gene therapy, nucleic acids, biologics and vaccines). Alex joined Resilience from Genentech, where he was Vice President, Head of Business Development for Genentech Research and Early Development (gRED). Prior to Genentech, Alex held BD leadership roles at Merck Research Labs and the Novartis Institutes for BioMedical Research; was a co-founder of Zafgen and DARA Biosciences; and served as Director of Business Development in the Office of Technology Development at the Harvard Medical School.